Literature DB >> 17827824

Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease.

Widi Njaman1, Takafumi Iesaki, Yoshitaka Iwama, Yoshinari Takasaki, Hiroyuki Daida.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) has been identified as a life threatening complication of connective tissue disease. However, the association between serum uric acid (UA) levels and long-term outcome in PAH with connective tissue disease has not been evaluated. We therefore assessed whether serum UA levels are related to the mortality of such patients. METHODS AND
RESULTS: We investigated 90 consecutive patients with connective tissue disease who were initially diagnosed with PAH by echocardiography, and assessed the long-term clinical outcome in populations with higher (> or = 4.7 mg/dL) and lower serum UA levels. Kaplan-Meier analysis showed that patients with higher median serum UA values had a significantly worse survival rate for any cause of death (54.5% versus 84.7%, log-rank, P < 0.01) and PAH-related death (72.7% versus 93.4%, log-rank, P < 0.01) than those with low values. Multivariate analysis showed that an elevated serum UA level was an independent predictor for survival (hazard ratio, 1.88, 95% CI [1.24- 2.84], P < 0.01).
CONCLUSION: Elevated serum UA levels are associated with a poor prognosis and can serve as a prognostic predictor for patients with PAH secondary to connective tissue disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827824     DOI: 10.1536/ihj.48.523

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  6 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 2.  Biomarkers in pulmonary arterial hypertension.

Authors:  Julie L Rosenthal; Miriam S Jacob
Journal:  Curr Heart Fail Rep       Date:  2014-12

3.  Clinical Value of Asymmetrical Dimethylarginine Detection in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Authors:  Juan Liu; Qiang Fu; Lili Jiang; Youlian Wang
Journal:  Cardiol Res Pract       Date:  2019-08-14       Impact factor: 1.866

4.  Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study.

Authors:  Jingya Wang; Yuanyuan Wang; Xiaodi Li; Yingheng Huang; Xiaoxuan Sun; Qiang Wang; Miaojia Zhang
Journal:  BMC Pulm Med       Date:  2020-10-19       Impact factor: 3.317

5.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

Authors:  J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Oliver Distler; Dinesh Khanna; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; Martin Doelberg; Harbajan Chadha-Boreham; Harald Heinzl; Daniel M Rosenberg; Vallerie V McLaughlin; James R Seibold
Journal:  Ann Rheum Dis       Date:  2013-05-18       Impact factor: 19.103

6.  Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.

Authors:  Scott H Visovatti; Oliver Distler; J Gerry Coghlan; Christopher P Denton; Ekkehard Grünig; Diana Bonderman; Ulf Müller-Ladner; Janet E Pope; Madelon C Vonk; James R Seibold; Juan-Vicente Torres-Martin; Martin Doelberg; Harbajan Chadha-Boreham; Daniel M Rosenberg; Vallerie V McLaughlin; Dinesh Khanna
Journal:  Arthritis Res Ther       Date:  2014-12-10       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.